Concepedia

Daniel Wetterskog

DW

35

Publications

2.7K

Citations

24

H-Index

2004

Active since

Affiliations

Institute of Cancer Research(Current)

University College London

London Cancer

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Breast Cancer Now

Daniel Wetterskog is an author at Institute of Cancer Research specializing in medicine, cell biology, and oncology.

ORCID

Top concepts

Publications per year

2004–2025

35

Publications

35

Plasma <i>AR</i> and abiraterone-resistant prostate cancer

Alessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca et al. · Science Translational Medicine · 2015 · 431 citations · Full text

Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis

L. Johan Nissen, Renhai Cao, Eva–Maria Hedlund et al. · Journal of Clinical Investigation · 2007 · 282 citations · Full text

, , +17

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Vincenza Conteduca, Daniel Wetterskog, Mansour T. A. Sharabiani et al. · Annals of Oncology · 2017 · 263 citations · Full text

PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

Konstantin J. Dedes, Daniel Wetterskog, Ana M. Mendes‐Pereira et al. · Science Translational Medicine · 2010 · 252 citations

Synthetic lethality of PARP inhibition in cancers lacking<i>BRCA1</i>and<i>BRCA2</i>mutations

Konstantin J. Dedes, Paul M Wilkerson, Daniel Wetterskog et al. · Cell Cycle · 2011 · 186 citations · Full text

, , +12

Rows per page

1–5 of 35